Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Abbott Laboratories (NY: ABT)
36.59 USD  -0.24 (-0.65%)
Official Closing Price  /  Updated: 6:40 PM EDT, May 17, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Abbott Laboratories
 
< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Abbott Japan and Eisai have Cleared the Condition for Approval of Humira(R), a Fully Human Anti-TNF-Alpha Monoclonal Antibody, for Plaque Psoriasis and Psoriasis Arthropica in Terms of the All-Case Su
April 23, 2012
from JCN Newswire
Abbott and St. Jude Medical Broaden Alliance for Cardiovascular Products in the United States
April 23, 2012
from Business Wire News Releases
Abbott and St. Jude Medical Broaden Alliance for Cardiovascular Products in the United States
April 23, 2012
- Builds Upon Existing Alliance and Allows Both Companies to Offer a Comprehensive Cardiovascular Portfolio to U.S. Customers Read More
from PR Newswire
Abbott Receives U.S. FDA Clearance to Use iFS Advanced Femtosecond Laser Technology for Arcuate Incisions in Cataract Surgery
April 20, 2012
from PR Newswire
Abbott Presents Positive Results from Phase 2 "Pilot" Study of an Interferon-Free Combination Regimen for the Treatment of Hepatitis C
April 19, 2012
Results among the Most Mature Data for an Interferon-Free Regimen, Including 36-Week Post-Treatment Sustained Viral Response for a 12-Week Treatment Regimen Read More
from PR Newswire
BioCurex Provides Shareholder Update on Recent Events at the Company
April 19, 2012
from GlobeNewswire News Releases
Abbott Presents Positive Results from Interferon-Free Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C
April 19, 2012
More than 90 Percent of Patients New to HCV Treatment Achieved Sustained Viral Response through 12 Weeks Read More
from PR Newswire
Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in First Quarter; Raises Full-Year 2012 Outlook
April 18, 2012
-- First Quarter Ongoing EPS of $1.03, Up 13.2 Percent -- Read More
from PR Newswire
Abbott's Investigational Treatment for Advanced Parkinson's Disease Demonstrates Positive Results in Phase 3 Clinical Trial
April 17, 2012
Statistically Significant Improvements in 'Off' Time Over Standard Oral Treatment; Data to Be Presented at American Academy of Neurology Annual Meeting Read More
from PR Newswire
Abbott Licenses Biomarkers for Use in Differentiating Aggressive from Nonaggressive Prostate Cancer
April 17, 2012
Detection of Gene Abnormalities May Help Men Determine the Best Approach to Treatment Read More
from PR Newswire
RBCC and N3D Forge Ahead with Bold Growth Strategy
April 13, 2012
from Business Wire News Releases
RBCC: New N3D Prototype Could be the Beginning of Something Big
April 12, 2012
from Business Wire News Releases
RBCC: Global Market for Neurodegenerative Therapies to Exceed $43.4 Billion by 2015
April 10, 2012
from Business Wire News Releases
Abbott Receives Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent in Japan
April 09, 2012
- Supported by Data from the SPIRIT Family of Clinical Trials, Which Demonstrated Strong Safety and Efficacy for XIENCE V® Read More
from PR Newswire
Most Attractive Stocks: Citigroup, Microsoft, Abbott, Texas Instruments, Atmel, and Monsanto
April 05, 2012
from PR Newswire
Abbott to Present Positive Phase 2 Results from Multiple Interferon-Free Studies of Combination Regimens for the Treatment of Hepatitis C
April 04, 2012
from PR Newswire
Abbott's PLEX-ID Molecular System and Tests for Broad Microbial Identification Obtain CE Marking
March 30, 2012
New PLEX-ID System and Three Clinical Tests Introduced in the European Union Read More
from PR Newswire
Abbott Hosts Conference Call for First-Quarter Earnings
March 28, 2012
from PR Newswire
RBCC: Michael J. Fox Foundation Invests $179 Million in the Fight Against Parkinson’s Disease
March 26, 2012
from Business Wire News Releases
RBCC Prepares to Join the $3 Billion Fight Against Parkinson’s Disease
March 23, 2012
from Business Wire News Releases
Analytical Reports on Abbott Laboratories and GlaxoSmithKline plc - Drug Manufacturers Facing Headwinds
March 23, 2012
from Marketwired News Releases
CER Research Responds to Abbott Laboratories on China Infant Formula Report
March 23, 2012
from PR Newswire
Abbott Laboratories Chinese Infant Formula Violates China National Standards, According to Tests
March 22, 2012
from PR Newswire
Abbott Selects AbbVie as New Name for Future Research-Based Pharmaceutical Company
March 21, 2012
Company Remains on Track for Separation into Two Publicly Traded Global Health Care Companies by End of 2012 Read More
from PR Newswire
Abbott Reinforces Global Vascular Leadership with New Data on Innovative Technologies at ACC 2012
March 20, 2012
Data to be Presented on Key Pipeline Products: MitraClip® System and Absorb™ Bioresorbable Vascular Scaffold Read More
from PR Newswire
N3D Unveils the Next Generation of 3D Cell Culturing System
March 20, 2012
from Business Wire News Releases
RBCC and n3D Aim to Help Bring Stem Cell Treatments to Market Faster
March 19, 2012
from Business Wire News Releases
RBCC Closes Deal with Game Changing Biotech Firm
March 15, 2012
from Business Wire News Releases
Abbott Announces Patient Enrollment in Two Phase 3 Studies of HUMIRA® (adalimumab) for Moderate to Severe Hidradenitis Suppurativa
March 15, 2012
Key Clinical Trials will Assess Drug's Efficacy and Safety; No FDA-Approved Treatment Exists Today for Patients with Moderate to Severe Cases Read More
from PR Newswire
RBCC: Promising New Parkinson’s Therapies May Also Treat Brain Injuries
March 14, 2012
from Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here